Human trials demonstrate that the PDE5 inhibitor sildenafil provides hemodynamic, symptomatic, and mortality benefits in HF with reduced ejection fraction, but not in HFpEJ [340,341,342]. The gene discussed is PDE5A; the disease is hydrops fetalis.